Details of the Drug

General Information of Drug (ID: DM1XT4N)

Drug Name
Tafenoquine
Synonyms 106635-80-7; WR-238605; WR 238605; Etaquine; WR238605; Tafenoquine [INN:BAN
Indication
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Approved [1]
Plasmodium vivax malaria 1F41 Approved [1]
Affected Organisms
Plasmodium
ATC Code
P01BA07: Tafenoquine
P01BA: Aminoquinolines
P01B: ANTIMALARIALS
P01: ANTIPROTOZOALS
P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 463.5
Logarithm of the Partition Coefficient (xlogp) 5.4
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 13.8 h [2]
Clearance
The clearance of drug is 6 L/h [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 14 days [3]
Metabolism
The drug is metabolized via the liver [2]
Vd
The volume of distribution (Vd) of drug is 2 560 L [2]
Chemical Identifiers
Formula
C24H28F3N3O3
IUPAC Name
4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine
Canonical SMILES
CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC
InChI
InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3
InChIKey
LBHLFPGPEGDCJG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
115358
ChEBI ID
CHEMBL141487
CAS Number
106635-80-7
UNII
262P8GS9L9
DrugBank ID
DB06608
TTD ID
D07TWN
INTEDE ID
DR1526
ACDINA ID
D01454
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Electron transport complex III (Complex III) TTB8JQ7 CY1_HUMAN-CYB_HUMAN Inhibitor [1]
Reactive oxygen species (ROS) TTULV0X NOUNIPROTAC Modulator [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Haematite red E00236 14833 Colorant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tafenoquine 150 mg tablet 150 mg Tablet Oral
Tafenoquine 100 mg tablet 100 mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523.
2 Deshmukh R, Sharma L, Tekade M, Kesharwani P, Trivedi P, Tekade RK: Force degradation behavior of glucocorticoid deflazacort by UPLC: isolation, identification and characterization of degradant by FTIR, NMR and mass analysis. J Biomed Res. 2016 Mar;30(2):149-161. doi: 10.7555/JBR.30.20150074. Epub 2016 Feb 20.
3 Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. Int J Nanomedicine. 2015 Feb 20;10:1493-503. doi: 10.2147/IJN.S76317. eCollection 2015.
4 Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99.